# Sedana Medical > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/sedanamedical). ## Overview Sedana Medical is a Swedish company based in Danderyd that specializes in developing, manufacturing, and selling medical devices and pharmaceuticals. The company is renowned for its innovative therapy for inhaled sedation in intensive care units, which includes the Sedaconda ACD device and Sedaconda® (isoflurane). Sedana Medical is the parent company of the Sedana Medical Group and operates with a focus on high gross margins and a concentrated customer base, primarily hospitals with intensive care units. The company aims to make inhaled sedation a standard therapy across Europe and is preparing for a significant market entry into the United States. ## Products & services • Sedaconda ACD medical device • Sedaconda® (isoflurane) pharmaceutical • Accessories for inhaled sedation • Clinical trial services • Commercialization of inhaled sedation therapy - **Medical Devices** (40%) — Includes Sedaconda ACD for inhaled sedation - **Pharmaceuticals** (30%) — Includes Sedaconda® (isoflurane) for sedation - **Accessories** (15%) — Additional products supporting sedation therapy - **Clinical Trials** (10%) — Services related to clinical trials and research - **Commercialization Services** (5%) — Efforts to market and sell sedation therapies - Sedaconda ACD medical device - Sedaconda® (isoflurane) pharmaceutical - Accessories for inhaled sedation - Clinical trial services - Commercialization of inhaled sedation therapy ## Customers Sedana Medical primarily serves hospitals with intensive care units, focusing on those that require advanced sedation solutions. The company's products are designed to meet the needs of healthcare providers looking for effective and efficient sedation methods. Customers value Sedana Medical's innovative approach to inhaled sedation, which offers potential benefits over traditional intravenous methods. The company's concentrated customer base allows for targeted marketing and sales efforts, enhancing profitability. Sedana Medical's strategic focus on the US market aims to expand its customer base significantly. - **Hospitals** (primary) — Purchase Sedaconda ACD and Sedaconda® for ICU sedation - **Healthcare Providers** (primary) — Use inhaled sedation for efficient patient care - **Clinical Research Organizations** (secondary) — Engage in clinical trials for sedation therapies - Hospitals with intensive care units - Healthcare providers seeking advanced sedation solutions - Customers valuing innovative inhaled sedation methods - Targeted marketing to concentrated customer base - Expansion into the US market to grow customer base ## Geography Sedana Medical is headquartered in Danderyd, Sweden, and has a strong presence across Europe, with market authorizations in 15 countries. The company is actively preparing for entry into the United States, which represents its largest potential market. Sedana Medical's products are approved and sold in over 40 countries, leveraging both direct sales teams in Europe and distributors globally. The acquisition of Innovatif Cekal in Malaysia enhances supply chain control and profitability. - Headquartered in Danderyd, Sweden - Strong presence in 15 European countries - Preparing for US market entry - Products sold in over 40 countries - Acquisition of Innovatif Cekal in Malaysia for supply chain control ## Strategy Sedana Medical's strategic priorities include achieving profitable sales growth in Europe, maximizing opportunities in the US, and building a long-term profitable company. The company aims to make inhaled sedation a standard therapy in intensive care units. With FDA fast track designation for its Phase III clinical program, Sedana Medical is poised for a significant US market launch. The acquisition of Innovatif Cekal supports the company's strategy by enhancing supply chain efficiency and profitability. - **Profitable Sales Growth in Europe** (medium-term) — To establish inhaled sedation as a standard therapy - **US Market Entry** (long-term) — Largest potential market with high ICU bed count - **Long-term Profitability** (long-term) — High gross margins and concentrated customer base - Achieve profitable sales growth in Europe - Maximize US market opportunities - Make inhaled sedation a standard therapy - FDA fast track designation for US launch - Enhance supply chain efficiency through acquisitions ## Risks Key risks for Sedana Medical include regulatory approval challenges in the US, competition from established sedation methods, and fluctuations in ICU occupancy rates affecting sales. The company's reliance on a concentrated customer base could impact revenue stability. Additionally, currency fluctuations and supply chain disruptions pose financial risks. The acquisition of Innovatif Cekal mitigates some supply chain risks but introduces integration challenges. - **Regulatory Approval in US** [critical] — Critical for market entry and revenue growth - **Competition** [high] — Established intravenous sedation methods - **ICU Occupancy Rates** [medium] — Directly impacts sales volume - **Currency Fluctuations** [medium] — Impacts financial performance due to international operations - Regulatory approval challenges in the US - Competition from established sedation methods - Fluctuations in ICU occupancy rates - Reliance on a concentrated customer base - Currency fluctuations affecting financial performance - Supply chain disruptions - Integration challenges post-acquisition ## Accounting Sedana Medical's financial statements are influenced by currency effects from intragroup loans, which are now reported as part of net financial items rather than operating expenses. This change affects the presentation of operating profit. The company also deals with seasonality in ICU occupancy, impacting quarterly revenue fluctuations. Short-term investments in SEK and USD are valued at amortized cost, affecting reported financial assets. The acquisition of Innovatif Cekal introduces considerations for goodwill and integration costs. - **Currency Effects** - **Seasonality** - **Short-term Investments** - **Goodwill and Integration Costs** - Currency effects from intragroup loans impact financial items - Seasonality in ICU occupancy affects quarterly revenue - Short-term investments valued at amortized cost - Goodwill and integration costs from acquisitions --- *Last updated: 2026-08-11T04:04:55.727453+00:00*